GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » PB Ratio

SinoMab BioScience (HKSE:03681) PB Ratio : 6.93 (As of Apr. 25, 2025)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-25), SinoMab BioScience's share price is HK$1.31. SinoMab BioScience's Book Value per Share for the quarter that ended in Jun. 2024 was HK$0.19. Hence, SinoMab BioScience's PB Ratio of today is 6.93.

Warning Sign:

SinoMab BioScience Ltd stock PB Ratio (=6.51) is close to 5-year high of 7.14.

The historical rank and industry rank for SinoMab BioScience's PB Ratio or its related term are showing as below:

HKSE:03681' s PB Ratio Range Over the Past 10 Years
Min: 1.32   Med: 2.61   Max: 7.14
Current: 6.89

During the past 8 years, SinoMab BioScience's highest PB Ratio was 7.14. The lowest was 1.32. And the median was 2.61.

HKSE:03681's PB Ratio is ranked worse than
81.79% of 1285 companies
in the Biotechnology industry
Industry Median: 2.23 vs HKSE:03681: 6.89

During the past 12 months, SinoMab BioScience's average Book Value Per Share Growth Rate was -39.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -38.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -32.60% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of SinoMab BioScience was 198.90% per year. The lowest was -38.90% per year. And the median was -29.75% per year.

Back to Basics: PB Ratio


SinoMab BioScience PB Ratio Historical Data

The historical data trend for SinoMab BioScience's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience PB Ratio Chart

SinoMab BioScience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial 3.87 3.45 3.29 5.38 5.77

SinoMab BioScience Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.29 4.15 5.38 6.15 5.77

Competitive Comparison of SinoMab BioScience's PB Ratio

For the Biotechnology subindustry, SinoMab BioScience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's PB Ratio distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's PB Ratio falls into.


;
;

SinoMab BioScience PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

SinoMab BioScience's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=1.31/0.189
=6.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


SinoMab BioScience  (HKSE:03681) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


SinoMab BioScience PB Ratio Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SinoMab BioScience Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Liu Wenyi 2201 Interest of corporation controlled by you
Qiang Jing
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Leung Shui On 2201 Interest of corporation controlled by you
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience Headlines

No Headlines